

Notice of Allowability

Application No.

10/071,890

Examiner

Hector M Reyes

Applicant(s)

FRANGIONI, JOHN V.

Art Unit

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 01/16/04.
2. ☒ The allowed claim(s) is/are 17, 21-65 and 67, renumbered as 1-47.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.


THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____
7. ☐ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.


PAUL J. KILLOS
PRIMARY EXAMINER

Art Unit: 1625

DETAILED ACTION

Status of the Claims

Claims 1-16, 18-20 and 66 have been canceled. Claims 37-42 have been amended. Currently, claims 17, 21-65 and 67 are under Examination. The Examiner has renumbered the said active claims as claims 1 to 47.

Allowance

The following is an examiner's statement of reasons for allowance: Applicants claim:

- In re-numbered claims 1-24 a series of compounds as described on such claims.
- In re-numbered claims 25, pharmaceutical compositions comprising the claimed compounds
- In renumbered claims 26-43 methods for detecting or imaging or determining the abundance of PMSA or methods to diagnose a prostate disease condition comprising the claim compounds, as described in the said claims
- In claims 44-47 a Kit for diagnosing or detect PMSA comprising the claimed compounds as described in the said claims.

No prior art disclosing or suggesting the claimed compounds was found in the prior art. The closest art relevant to Applicant's instant invention was found in:

- Valiaeva et al J. Organic Chemistry, 2001, vol. 66 pages 5146-5154 or
- Tokutake et al, Bioorganic & Medicinal Chemistry, vol. 6, no. 10 pages 1935-1953 (1998) or
- Katoh et al, Bioorganic & Medicinal Chemistry, vol. 6 no 13, pages 1437-1442 (1996).

Art Unit: 1625

Valiaeva discloses a series of pseudopeptides analogues useful in the inhibition of Folyl-poly-gamma glutamate synthetase; Tokutake discloses the synthesis and Evaluation of transition states analogue Inhibitors of E. coli gamma glutamylcysteine Synthetase and Katoh et al discloses analogues inhibitors of E. coli gamma glutamylcysteine Synthetase. The cited references, however do not disclose or suggest the compounds described in the instant invention.

CONCLUSION

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."


All post-Allowance Correspondence concerning this Application must be mailed to:

**BOX ISSUE FEE
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231**

Or you can fax them to the Office of Patent Publications at 703-308-5083, in order to expedite the handling of such correspondence as amendments under 37 CFR 1.312; information disclosure statements, and formal drawings. Sending Post-Allowance papers to Technology Center 1600 will only cause delays in matching papers with the case.

For information concerning status of correspondence sent after receipt of the Notice of Allowance, please contact the Correspondence Branch at (703) 305-8027.

**Héctor M. Reyes, PhD JD
Reg. # 54, 846
February 9, 2004
AU 1625**


**PAUL J. KILLOS
PRIMARY EXAMINER**